[HTML][HTML] Identifying optimal ALK inhibitors in first-and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and …
Objectives To compare the efficacy, safety and effects on quality of life of different ALK-
inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung …
inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung …
The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross‐national comparison study
Y Jin, H Li, P Zhang, M Yu, H Zhang… - International Journal of …, 2023 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) are currently one of the most popular treatment methods
for cancers. Several ICIs have been approved in China and the United States. We created a …
for cancers. Several ICIs have been approved in China and the United States. We created a …
PD-(L) 1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data
Y Ge, Y Zhan, J He, J Li, J Wang, X Wei… - Journal of Cancer …, 2024 - Springer
Background Chemotherapy combined with immune checkpoint inhibitors (IC), bevacizumab
(BC), or both (IBC) is the preferred first-line therapy for PD-L1-negative and oncogenic-driver …
(BC), or both (IBC) is the preferred first-line therapy for PD-L1-negative and oncogenic-driver …
[PDF][PDF] 信迪利单抗联合化疗治疗局部晚期/转移性非小细胞肺癌的快速卫生技术评估
陈昕怡， 赵程程， 席庆 - 临床药物治疗杂志, 2023 - lcywzlzz.com
目的评价信迪利单抗联合化疗治疗局部晚期/转移性非小细胞肺癌(NSCLC) 的有效性,
安全性和经济性. 方法检索PubMed, Embase, the Cochrane Library, 中国期刊全文数据库 …
安全性和经济性. 方法检索PubMed, Embase, the Cochrane Library, 中国期刊全文数据库 …
Role of ICIs-Based Therapies and Bevacizumab for Advanced Wild-Type Non-Squamous NSCLC in the First-Line Setting: A Bayesian Network Analysis
S Yang, Z Lingling, X Wenwen, X Jinmin… - Available at SSRN … - papers.ssrn.com
Aims: Few studies directly compare the efficacy and safety of advanced non-small cell lung
cancer patients with wild-type for current first-line treatment. Therefore, We compared the …
cancer patients with wild-type for current first-line treatment. Therefore, We compared the …
[HTML][HTML] What APs Need to Know: RET-Mutated Non-Small Cell Lung Cancer
M May, B Sandy - conversations.advancedpractitioner …
Megan May, PharmD, BCOP, FAPO, FHOPA, and Beth Sandy, MSN, CRNP, review the use
of next-generation sequencing and the newer RNA-sequencing to test for RET mutations …
of next-generation sequencing and the newer RNA-sequencing to test for RET mutations …